Research · Sep 3, 2026
[DHR] Danaher Thesis 2026: Cytiva Bioprocessing Recovery + DBS Discipline Anchor Life Sciences Compounding
Danaher FY2025 revenue ~$24.5B (+3-5%) with adj. operating margin ~27% — second year as focused life sciences + diagnostics + biotechnology company post-Veralto Sep 2023 spinoff. Biotechnology segment (Cytiva $21B + Pall $13.8B = ~$8B revenue) recovering from FY2023-2024 bioprocessing inventory destocking. Cepheid GeneXpert COVID revenue substantially wound down (>$3B FY2021 peak → minimal). Cytiva MabSelect protein A resin = industry-standard for monoclonal antibody purification — high switching costs. FY2026 thesis: biopharmaceutical capex re-acceleration on GLP-1 manufacturing + biosimilars + gene therapy commercialization → Cytiva/Pall demand normalizes; Diagnostics core stabilizes post-COVID; DBS-driven margin expansion continues; key risks: biopharma funding constraint extends, China research market deterioration, Cepheid molecular competitive intensity (BioFire/BioMerieux).